Login to Your Account

Dezima's CETP inhibitor hits phase IIb endpoint

By Cormac Sheridan
Staff Writer

Tuesday, September 2, 2014
DUBLIN – Dezima Pharma BV is on track to move its highly potent cholesteryl ester transfer protein (CETP) inhibitor TA-8995 (DEZ-001) into a phase III program in the first quarter of next year, following a phase IIb dyslipidemia trial, which the drug passed with flying colors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription